H
COAG
HEMAB THERAPEUTICS HOLDINGS
50.09
+3.57+7.67%Pre Market: 51.00 +0.91 +1.82%04:56 08/06 EDT
OPEN/PREV CLOSE50.20/50.09
TODAY RANGE49.80-53.61
VOL22
MARKET CAP2.44B
52 WEEK RANGE23.00-53.61
AVG VOL (3M)315.62K
% TURNOVER0.60%
TURNOVER--
P/E (TTM)-101.5972
% RANGE7.20%
EPS(TTM)-0.5134
P/E(FORWARD)-19.2472
P/B14.27
BVPS3.656
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP2.17B
SHARES OUTSTANDING46.71M
NEXT EARNINGS--
FREE FLOAT41.67M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Seeking Alpha·07/23 11:18
Biotech stocks lead healthcare's overbought list as earnings picks up
NASDAQ·07/21 07:41
Biotech Stocks At 52-Week Highs - XNCR, COAG, MNPR, SOPH, ACRS
NASDAQ·07/15 11:08
Hemab Presents Sutacimig Data; Wedbush Rates Outperform, $55 Target
Seeking Alpha·07/15 07:52
Hemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical Catalysts
TipRanks·07/14 11:50
Hemab Therapeutics presents sutacimig data at ISTH Congress
NASDAQ·07/14 08:03
Biotech Stocks At 52-Week Highs - COAG, ALMR, PGNY, TXG, VMD
Seeking Alpha·07/14 07:55
Mega-Deals Push H1 2026 U.S. Equity Issuance Into Orbit
TipRanks·07/13 18:50
Analysts Are Bullish on Top NA Stocks: HawkEye 360, Inc. (HAWK), SpaceX (SPCX)
Dow Jones·07/13 18:48
Hemab Therapeutics Hldgs Is Maintained at Buy by Jefferies
Benzinga·07/13 18:39
Jefferies Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $47
Benzinga·07/13 17:47
Hemab Advances Bleeding Disorder Pipeline
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.